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ASSESSING THE QUALITY OF QUALITY OF LIFE MEASURES IN HEART 
FAILURE: A COMPARISON OF AVAILABLE INSTRUMENTS
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Valderas JM5, Alonso J3
1CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Cataluña, Spain, 2Hospital 
Vall d’Hebrón, Barcelona, Cataluña, Spain, 3Institut Municipal d’Investigació Mèdica, Barcelona, 
Cataluña, Spain, 4Catalan Agency for Health Technology Assessment and Research, 
Barcelona, Cataluña, Spain, 5University of Manchester, Manchester, UK
OBJECTIVES: To evaluate and compare the performance of available disease-speciﬁc 
health-related quality of life (HRQL) instruments for use in heart failure. METHODS: 
A systematic review identiﬁed 5 disease-speciﬁc HRQL questionnaires for use in heart 
failure (Minnesota Living with Heart Failure questionnaire [MLHFQ], Chronic Heart 
Failure questionnaire [CHFQ], Kansas City Cardiomyopathy questionnaire [KCCQ], 
Left Ventricular Disease Questionnaire [LVDQ], and the Quality of Life in Severe 
Heart Failure Questionnaire [QLSHFQ]). The 5 questionnaires were evaluated using 
EMPRO (Evaluating Measures of Patient Reported Outcomes), a tool for the stan-
dardized assessment of the psychometric properties and usability of patient reported 
outcome measures. Groups of four expert appraisers evaluated 8 attributes for each 
instrument and gave an overall recommendation after a consensus procedure. Scores 
ranged from 0 (worst possible score) to 100 (best possible score). Inter-rater agreement 
(intra-class correlation coefﬁcient – ICC) was analyzed and median scores and ranges 
for all EMPRO attributes were calculated. An overall recommendation was provided 
(highly recommended, recommended with provisos, not recommended, unsure). 
RESULTS: Inter-rater agreement for EMPRO was generally acceptable (ICC of 0.48 
– 0.93 for individual attributes). Median overall EMPRO ratings and attribute score 
ranges were: MLHFQ (59.8, 33.3–69.4), CHFQ (54.9, 38.1–72.2), KCCQ (47.2, 
38.1–100), LVDQ (47.7, 11.1–76.7), and QLSHFQ (7.7, 5.6–26.6). The highest 
scores for all instruments except the QLSHFQ were on responsiveness (median scores 
from 5.6 to 100). Three of the questionnaires (MLHFQ, CHFQ, KCCQ) were recom-
mended with provisos; the LVDQ and QLSHFQ were not recommended. CONCLU-
SIONS: Of the 5 instruments evaluated, 2 (MLHFQ, CHFQ) scored well on EMPRO 
and were recommended, whilst the others may be limited to use in particular types of 
study or require further investigation. This type of assessment can provide useful 
information for questionnaire selection. Funding: This work was supported by grants 
from Instituto de Salud Carlos III FEDER, (PI08/90724).
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EXPLORING PATIENTS’ SATISFACTION WITH ANTICOAGULANT 
TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO 
THE PERCEPTION OF ANTICOAGULANT TREATMENT 
QUESTIONNAIRE (PACT-Q)
Regnault A1, Gilet H1, Carita P2, Arnould B3
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OBJECTIVES: To explore the process of patients’ satisfaction with anticoagulant         
treatment using Structural Equation Modeling (SEM). METHODS: The Perception  
of AntiCoagulant Treatment Questionnaire (PACT-Q) includes 2 modules: a 7-item 
module assessing patient expectations of anticoagulant treatment and a 20-item 
module assessing treatment convenience and patient satisfaction. It was completed by 
deep venous thrombosis, atrial ﬁbrillation and pulmonary embolism patients in 3 
clinical trials assessing anticoagulant treatments. The ﬁrst module was administered 
at baseline (BL) and the second after 3 (M3) and 6 months (M6). SEM was applied 
to pooled data from the three trials. SEM speciﬁcations were supported by the ques-
tionnaire conceptual model, satisfaction theory and the scoring rules of the instrument. 
The goodness of ﬁt of the models was assessed using a set of commonly used ﬁt indices 
including the Root Mean Square of Approximation (RMSEA). Association between 
latent variables was assessed using Standardized Path Coefﬁcients (SPC). RESULTS: 
A total of 986 patients had fully completed PACT-Q at BL, M3 and M6. PACT-Q 
items allowed good measurement of Convenience (RMSEA  0.054) and Satisfaction 
(RMSEA  0.028) at M3. The 7 expectation items were kept independent. An overall 
model involving two expectation items (expectations of symptom relief, worries about 
making mistakes) and both Satisfaction and Convenience at M3 and M6 was esti-
mated (RMSEA  0.032). In this ﬁnal model, Convenience had a stronger impact on 
Satisfaction at M3 than at M6 (respective SPC: 0.57 vs 0.48). Convenience at M6 was 
very strongly related with Convenience at M3 (SPC: 0.80) while the relationship 
between Satisfaction at M3 and M6 was weaker (SPC: 0.52). CONCLUSIONS: The 
application of SEM to the PACT-Q data allowed the prominent role of patients’ 
expectations and perception of treatment convenience in the process of anticoagulant 
treatment satisfaction to be highlighted. Convenience was also shown to be more 
stable over time than satisfaction.
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UNITED STATES, EUROPE, AND JAPAN
Wagner S1, Fukuda T2, Nagae T3, Gupta S1, DiBonaventura M1, Stankus AP1
1Consumer Health Sciences International, Princeton, NJ, USA, 2University of Tokyo, Bunkyo, 
Tokyo, Japan, 3York Pharma KK, Tokyo, Japan
OBJECTIVES: To compare health-related quality-of-life (HRQoL) and resource use 
in patients with metabolic syndrome across three geographies. METHODS: Data used 
from the 2008 National Health and Wellness Survey (NHWS), an annual internet 
survey of adults in the US, EU (Germany, Spain, Italy, UK, and France), and 
Japan (JPN). Metabolic syndrome was deﬁned as having at least three of: diabetes, 
BMI  30, high cholesterol, or hypertension. Resource use included emergency room 
(ER) visits, hospitalizations, and visits to traditional health care providers. Linear 
regression was used to determine the effects of geography on the physical component 
summary score (PCS) and mental component summary score (MCS) of the SF-12, and 
Poisson regression for resource use, controlling for age, gender and total number of 
comorbidities. RESULTS: Of the 11,131 patients with metabolic syndrome 2,503, 
185 and 8,443 were from EU, JPN, and US, respectively. All prevalence numbers were 
signiﬁcantly different from one another (p  0.05). Mean MCS scores were 45.86, 
45.84, and 47.39 for EU, JPN and US, respectively, with a signiﬁcant difference 
between EU and US (p  0.05). The PCS score for JPN (44.86) was signiﬁcantly higher 
than both US (38.76) and EU (38.41) PCS scores (p  0.05). After controlling for 
confounders, JPN MCS scores were 2.87 points lower than the US (p  0.05), while 
EU scores were 2.09 points lower (p  0.05). JPN PCS scores were 4.92 points higher 
(p  0.05), and EU scores were 1.22 points lower than the US (p  0.05). The regres-
sion results for resource use showed JPN with fewer ER visits than US, and both JPN 
and EU with more hospitalizations, and more provider visits (p  0.05). CONCLU-
SIONS: There are signiﬁcant differences in prevalence and possibly awareness of 
metabolic syndrome across the three regions. Also, signiﬁcant differences were seen 
in both HRQoL and resource use. Further research is needed to describe the burden 
of metabolic syndrome globally.
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IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF 
LIFE IN ATRIAL FIBRILLATION PATIENTS
Reynolds MR1, Hui G2, Zimetbaum P1
1Beth Israel Deaconess Medical Center, Boston, MA, USA, 2Harvard Clinical Research 
Institute, Boston, MA, USA
OBJECTIVES: Hospitalization is recognized as an important endpoint in atrial ﬁbril-
lation (AF) clinical trials. The association between hospitalization and reduced health-
related quality of life (HRQOL) has not been studied. Therefore, a large AF registry 
was used to characterize the impact of hospitalization on HRQOL. METHODS: The 
FRACTAL study was an observational registry of patients enrolled in the United States 
and Canada with new-onset AF. HRQOL was assessed with the SF-12 and the AF 
Symptom Checklist at baseline, 3, 6, and 12, 24 and 30 months. Mixed linear regres-
sion models were ﬁtted to estimate the impact of hospitalization on HRQOL summary 
scores (physical and mental component scores of SF-12, symptom frequency and 
severity, and utilities from the SF-12), adjusting for demographic and clinical variables 
known to inﬂuence HRQOL in this population. RESULTS: Of 933 subjects who 
completed HRQOL questionnaires and were not hospitalized during the baseline study 
visit, 303 (32%) were hospitalized a total of 490 times during an average of 2.0 years 
of follow-up. The majority (64%) of these admissions were for cardiovascular causes. 
The adjusted effect of any hospital admission (vs. none) on symptom frequency and 
severity scores over time was 1.3 and 1.1 points, respectively (p  0.01 for both), 
with higher scores indicating greater symptom burden. The adjusted effect of any 
admission on the SF-12 physical score was 2.7 points (p  0.0001) and a decrement 
on utility of 0.03 (p  0.0001). In contrast, hospitalization had little effect on longi-
tudinal SF-12 mental scores (0.7 points, p  0.15). CONCLUSIONS: In a real life 
long term AF registry, hospitalizations during follow-up were associated with signiﬁ-
cant increases in AF symptoms and decrements in generic physical HRQOL and utili-
ties. Based on these results which may be limited by the study design, interventions 
that reduce hospital admissions in AF patients would be expected to improve or 
 preserve HRQOL.
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OBJECTIVES: To assess whether the type of atrial ﬁbrillation (AF) could have a dif-            
ferent impact on patients’ HRQoL. METHODS: An observational, prospective, mul-   
ticentre study among 29 cardiologists specialized in arrhythmia, in the context of usual 
clinical practice was carried out to validate the AF-QoL questionnaire. AF patients 
(paroxysmal, persistent or permanent) were included. Variables recorded were age, 
NYHA scale, symptoms (number and frequency), emergency visits and AF-QoL score. 
RESULTS: A total of 341 AF patients were included (43% with persistent AF, 37%          
with paroxysmal AF and 20% with permanent AF). Paroxysmal AF patients were the 
youngest, with a mean age (SD) of 57(13) years, and reported better physical state, 
according to NYHA scale (67%, class I). Palpitations were the most prevalent 
symptom in paroxysmal AF patients (91%); dyspnea was the most prevalent symptom 
in persistent (70%) and permanent AF (77%). Paroxysmal AF patients reported the 
greatest number (4.5(2.5)) and frequency of symptoms (30% reported weekly symp-
toms), as well as the major number of emergency visits (2.2(1.7)) (p  0.05). Permanent 
AF patients showed better HRQoL in the psychological dimension of AF-QoL (47(28) 
points vs 38(26) and 37(26) in paroxysmal and persistent AF, respectively) (p  0.03). 
The rest of AF-QoL domains were similar between AF patients. The presence of 
symptoms was associated to a decrease in HRQoL in all AF patients, especially 
 palpitations in paroxysmal AF patients and palpitations, dyspnea and chest pain in 
permanent AF. Moreover, the more frequent the symptoms, the lower the AF-QoL 
score (p  0.05). A correlation was observed between the increase of emergency visits 
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and the decrease in AF-QoL score, particularly in paroxysmal and persistent AF 
patients. CONCLUSIONS: The main impact on HRQoL in AF patients was not          
 conditioned by the type of AF, but the clinical presentation, especially number and 
frequency of symptoms.
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EXPERIENCE WITH UPPER GASTROINTESTINAL SYMPTOMS IN 
PATIENTS WITH CARDIOVASCULAR RISK TREATED WITH LOW-DOSE 
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OBJECTIVES: To describe the experience with upper gastrointestinal (GI) symptoms, 
the impact of symptoms on daily life, and nonadherence and discontinuation of low-
dose acetylsalicylic acid (ASA) treatment in patients with cardiovascular (CV) risk. 
METHODS: Twenty-two patients from the US were selected to undergo face-to-face, 
1-hour qualitative interviews following a multicentre 3-month observational study of 
patients q18 years at risk of or with CV disease, about to begin or previously pre-
scribed daily low-dose ASA (75–325 mg) within 5 years (ClinicalTrials.gov identiﬁer: 
NCT00681759; AstraZeneca study code: D961FC00004). Interviewee-selection was 
based on low-dose ASA history, CV risk, GI medication use, and the occurrence of 
q1 upper GI event during the study period. Interviews were semi-structured and were 
audio-recorded and transcribed for analysis. RESULTS: 16 interviews were evaluable 
(mean age 44.7 years; 68.8% women); 6 patients were excluded following technical 
failure or violation of inclusion/exclusion criteria. Commonly reported upper GI 
symptoms were: burning feeling behind the breastbone (n  9); burning feeling in the 
upper stomach (n  4); acid taste in the mouth (n  4); regurgitation (n  4). Upper 
GI symptoms negatively impacted aspects of patients’ lives, including: food intake 
(n  12); sleep quality (n  6); emotions (n  5). Most patients reported occasional 
over-the-counter medication use; many altered their diet to manage upper GI symp-
toms. Overall, ﬁve patients reported treatment nonadherence. Upper GI symptoms 
caused nonadherence in 3 patients; 2 missed doses when GI symptoms were severe, 
despite being aware of low-dose ASA beneﬁts. Patients who understand the purpose 
of their low-dose ASA prescription could articulate the importance of adherence and 
the intention to continue therapy. CONCLUSIONS: Patients who understand the 
purpose of low-dose ASA treatment are more likely to adhere to therapy, although 
doses may be intentionally missed due to upper GI symptoms.
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OBJECTIVES: In patients with chronic diseases such as hypercholesterolemia, health-
related quality of life (HRQoL) is an important outcome. The objective of the present 
study was to determine factors associated with an impaired HRQoL after 12 months. 
METHODS: Patients with hypercholesterolemia were prospectively included in the 
ORBITAL (Open-label primary care study: Rosuvastatin-Based compliance Initiatives 
linked To Achievement of LDL goals) Study. Inclusion criteria were hypercholestero-
lemia with an indication for statin therapy according to the European Guidelines. 
Follow-up was 12 months. A total of 1961 primary care practices in Germany par-
ticipated. HRQoL was assessed with the Short Form (SF)-12 health status instrument. 
RESULTS: Of the 7640 patients included, 47% were high-risk patients in the primary 
prevention of coronary heart disease, 42% were patients with coronary heart disease, 
and 11% did not have a priori risk stratiﬁcation. Physical SF-12 summary scores were 
inversely associated with risk stratum, however, there was no such association between 
mental SF-12 summary scores and risk stratum. An impaired physical SF-12 score was 
associated with increased age, lower educational level, higher body mass index, 
smoking, existing coronary heart disease, a history of stroke, or a clinical event during 
follow-up. An impaired mental SF-12 score was associated with younger age, hyper-
tension, or a clinical event during follow-up. CONCLUSIONS: HRQoL in patients 
with hypercholesterolemia is associated with socioeconomic factors, lifestyle, and 
clinical events. Effective prevention is thus not only essential for clinical outcome 
but also for the maintenance of HRQoL in patients with hypercholesterolemia. 
ClinicalTrials.gov Identiﬁer: NCT00379249.
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OBJECTIVES: The assessment of quality of life among ambulatory patients with 
hypertension (HTN), diabetes type 2 (DM2) or coexisting HTN and DM2 
(HTNDM2). METHODS: Patients of 4 ambulatory care setting in Cracow (Poland) 
with HTN, DM2 or HTNDM2 were included. Polish versions of SF-36v.2 and EQ-
5D were used with the supplementary questions about age, gender, education, body 
mass, place of residence. Student’s t-test was used to compare the differences between 
paired groups. RESULTS: A total of 135 patients were included (68 with HTN, 22 
with DM2, 45 with HTNDM2); 57,8% of patients were women. 31,11% of patients 
with HTNDM2, 36,77% of patients with HTN and 72,73% of patients with DM2 
assessed their health status as well, none indicated the answer excellent or very good. 
Usually women indicated their QOL lower than men (HTN: PF, RP, PCS p  0,05; 
HTNDM2: PF, PB p  0,05). PCS was rated lower or similar to MCS; HTN: PCS 
39,30 o 7,88, MCS 40,45 o 10,96, DM2: PCS 42,77 o 8,22, MCS 42,23 o 9,86; 
HTNDM2: PCS 38,89 o 9,05, MCS 42,66 o 10,66. Due to EQ-5D 80% of patients 
had no problems with self care and 60% – with usual activities. Over 85% of patients 
had moderate or extreme pain or discomfort, more than 70% of patients felt moder-
ately or extremely anxious or depressed. About 75% of patients with HTN and 
HTNDM2 conﬁrmed problems with walking around. On VAS scale, patients with 
HTN, DM2 and HTNDM2 assessed their health state accordingly: 54,87 o 15,70, 
59,14 o 21,06, 55,56 o 14,50, with no statistically signiﬁcant differences between 
diseases and sexes. CONCLUSIONS: Patients with HTN and HTNDM2 estimated 
their quality of life lower than patients with DM2.
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OBJECTIVES: To investigate the differences in work productivity in patients with 
metabolic syndrome across three geographies. METHODS: Data from the 2008 
National Health and Wellness Survey (NHWS), an annual internet survey of attitudes, 
behaviors, health status, and outcomes of adults in the US, EU (Germany, Spain, Italy, 
UK, and France), and Japan (JPN) were used for the analysis. Metabolic syndrome 
was deﬁned as having at least three of the following: diabetes, BMI  30, high cho-
lesterol, or hypertension. Multiple regressions were used to determine the effect of 
geography on work productivity using the validated Work Productivity and Activity 
Impairment Questionnaire (WPAI) controlling for age, gender and total number of 
comorbidities. RESULTS: Of the 3,995 employed patients with metabolic syndrome 
in the analysis 881 (22.1%) were from Europe, 89 (2.2%) from JPN, and 3,025 
(75.7%) from the US. EU patients (10.9%) had signiﬁcantly higher levels of percent 
work missed in the past week due to health (absenteeism) than US (6.2%) and JPN 
(5.3%) patients. No signiﬁcant differences amongst geographies were seen for percent 
impairment at work (presenteeism), however, EU patients had higher levels of percent 
overall work impairment compared to US patients (p  0.05). For all metabolic 
patients (n  11,131) activity impairment was signiﬁcantly lower for JPN compared 
with US and EU (p  0.05). After controlling for age, gender and number of comorbid 
conditions, the differences remained signiﬁcant, with EU having higher absenteeism, 
overall work impairment, and activity impairment than the US, and JPN reporting 
less activity impairment than the US (p  0.05). CONCLUSIONS: The effect of meta-
bolic syndrome on work productivity differed signiﬁcantly across the three geogra-
phies. Any combination of factors may explain these differences: awareness of the 
condition, treatment differences, cultural issues, and health systems, amongst other. 
Further research is needed to describe the impact metabolic syndrome may have 
globally.
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OBJECTIVES: Although cardiovascular disease remains a major cause of death and 
morbidity in western countries, statins are well recognized for their role in prevention. 
The on-going need to maintain cost-effective health care has led to greater use of 
policy-driven therapeutic substitution programs for statins; however the impact of 
these policies on patients is often under-reported. METHODS: A review of published 
literature describing the impact of policy-driven statin switch programs was conducted 
based on a MEDLINE search [using the following terms: Hydroxymethylglutaryl-CoA 
Reductase Inhibitors (MeSH), and statin, switch, interchange, substitute, substitution 
(all ﬁelds); limited to English language and 1989–2009] and a review of reference lists 
from selected papers. RESULTS: Twenty-three studies were identiﬁed. Seventeen 
studies evaluated the impact of a “switch down” to equal or less potent statins. 6 
studies evaluated the impact of a “switch up” to more potent statins. Following 
introduction of “switch down” programs, 23–47% of patients were not eligible or 
willing to switch (7 studies), 17–38% of patients were switched to a non-equivalent 
(lower) dose of the new statin (3 studies), 4–11% of patients switched back to their 
original statin (5 studies), and switched patients were 19–33% less likely to be adher-
ent to therapy compared to those with no switch. Persistence was signiﬁcantly reduced 
among switch patients (2 studies). No signiﬁcant trend in lipid levels was noted (12 
studies) but loss of target levels was reported in 7–20% of patients (2 studies) and 3 
studies reported an increase in vascular events or death after switching. Studies evalu-
ating “switch up” programs consistently demonstrated improved reductions in lipid 
